Factory price LUMIRACOXIB CAS 220991-20-8 | China | Manufacturer

Price	Get Latest Price
Package	25KG

Product Details

Product Name: LUMIRACOXIB	CAS No.: 220991-20-8
EC-No.: 1308068-626-2	Min. Order: 1KG
Purity: 99%	Supply Ability: 50000KG/month
Release date: 2023/08/29

CAS:	220991-20-8
MF:	C15H13ClFNO2
MW:	293.72
EINECS:	1308068-626-2
Product Categories:	Inhibitors;PREXIGE;Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	220991-20-8.mol

LUMIRACOXIB Chemical Properties

Melting point	139-141°C
Boiling point	395.7±42.0 °C(Predicted)
density	1.363±0.06 g/cm3(Predicted)
storage temp.	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility	≥29.4 mg/mL in DMSO; insoluble in H2O; ≥27.15 mg/mL in EtOH with ultrasonic
pka	4.18±0.10(Predicted)
form	solid
CAS DataBase Reference	220991-20-8

LUMIRACOXIB Usage And Synthesis

Description	As a second-generation, selective cyclooxygenase (COX-2) inhibitor, lumiracoxib is devoid of the gastrointestinal issues that plague other non-selective, nonsteroidal, anti-inflammatory drugs (NSAIDs) that crossover to COX-1. As an inhibitor of the inducible COX-2 that is up-regulated in pathological processes of pain and inflammation, lumiracoxib blocks the conversion of arachidonic acid to prostaglandins, the mediators of the pathological effects. It’s mode of binding to COX-2 has been found to differ from the other selective COX-2 inhibitors; the carboxylic acid forms hydrogen bonds with Tyr-385 and Ser-530 in the catalytic site rather than seeking interactions within the larger hydrophobic side pocket. Since lumiracoxib is mainly metabolized by CYP2C9, a study evaluating the co-administration of lumiracoxib with fluconazole, a potent inhibitor of CYP2C9, was conducted, and it concluded that there was no need for lumiracoxib dose adjustment, since changes in the systemic exposure were not significant. No serious adverse effects were reported, but in the small number of cases where treatment was discontinued, Gastro intestinal (GI) and musculoskeletal complaints were common.
Description	Lumiracoxib is a selective inhibitor of COX-2 with IC₅₀ values of 0.13 and 67 μM for COX-2 and COX-1, respectively, in isolated human whole blood. It reduces increases in the levels of prostaglandin E₂ (PGE₂; ) induced by IL-1β in human dermal fibroblasts (IC₅₀ = 0.14 μM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 μM., Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE₂ in a rat model of air pouch inflammation. It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.
Chemical Properties	Pale Yellow Solid
Originator	Novartis AG (Switzerland)
Uses	Lumiracoxib is a selective cyclooxygenase-2-(COX-2) inhibitor and an anti-inflammatory agent (1,2,3,4).
Uses	Selective cyclooxygenase-2-(COX-2) inhibitor. Anti-inflammatory.
Uses	antiinflammatory, analgesic, antiarthritic
Definition	ChEBI: An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthrit s, but was withdrawn due to concersns of hepatotoxicity.
Brand name	Prexige
Biochem/physiol Actions	Lumiracoxib (COX189) is an orally active, potent and selective cyclooxygenase-2 inhibitor (Ki = 60 nM/COX-2 vs. 3.2 μM/COX-1) that inhibits COX-2-mediated PGE2 production in human whole blood (IC50 = 130 nM; stimulation = 50 μM A23187), but not COX-1-dependent TxB2 production (IC50 = 67 μM; stimulation = 10 μg/mL LPS). Lumiracoxib shows in vivo anti-inflammatory efficacy against carrageenan-induced paw oedema (ED30 = 0.35 mg/kg p.o.), CFA-induced hyperalgesia (ED30 = 5.1 mg/kg p.o.), as well as adjuvant-induced arthritis (ED50 = 3 mg/kg/day p.o.) in rats in vivo.

Product picture

Packing &shipping&Payment

Packing:25kg/drum
Shipping:by sea or by air
Payment:T/T,western union,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :

Quantity(Kilograms)	1 - 10000	>10000
Est. Time(days)	5	To be negotiated

Article illustration

Company information
Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in 4'-Methylacetophenone,Levamisole hydrochloride ,N-Methylformamide and other chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Advantage
In stock

Article illustration

Company Profile Introduction

-

Recommended supplier

Product name	Price		Suppliers	Update time
LUMIRACOXIB	$9.90/1KG	VIP6Y	Hebei Guanlang Biotechnology Co., Ltd.	2021-09-28
LUMIRACOXIB	$30.00/1Kg/Bag		Longyan Tianhua Biological Technology Co., Ltd	2020-11-09
LUMIRACOXIB	$2.00/1kg	VIP6Y	Career Henan Chemical Co	2018-12-23

LUMIRACOXIB NEW

Product Details

Company Profile Introduction

You may like

Recommended supplier

Hebei Mojin Biotechnology Co., Ltd

Min. Order:	1KG
Supply Ability:	50000KG/month
Update Time:	2023-08-29